aTyr Pharma Statistics
Total Valuation
aTyr Pharma has a market cap or net worth of $291.90 million. The enterprise value is $227.28 million.
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
aTyr Pharma has 88.86 million shares outstanding. The number of shares has increased by 38.53% in one year.
| Current Share Class | 88.86M |
| Shares Outstanding | 88.86M |
| Shares Change (YoY) | +38.53% |
| Shares Change (QoQ) | +9.13% |
| Owned by Insiders (%) | 2.27% |
| Owned by Institutions (%) | 57.16% |
| Float | 81.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,217.55 |
| Forward PS | n/a |
| PB Ratio | 3.72 |
| P/TBV Ratio | 4.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 967.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.48, with a Debt / Equity ratio of 0.19.
| Current Ratio | 5.48 |
| Quick Ratio | 4.93 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -79.88% and return on invested capital (ROIC) is -44.99%.
| Return on Equity (ROE) | -79.88% |
| Return on Assets (ROA) | -39.03% |
| Return on Invested Capital (ROIC) | -44.99% |
| Return on Capital Employed (ROCE) | -82.96% |
| Revenue Per Employee | $3,615 |
| Profits Per Employee | -$984,969 |
| Employee Count | 65 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +105.31% in the last 52 weeks. The beta is 0.96, so aTyr Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | +105.31% |
| 50-Day Moving Average | 3.43 |
| 200-Day Moving Average | 2.83 |
| Relative Strength Index (RSI) | 53.63 |
| Average Volume (20 Days) | 1,368,549 |
Short Selling Information
The latest short interest is 8.32 million, so 9.37% of the outstanding shares have been sold short.
| Short Interest | 8.32M |
| Short Previous Month | 6.92M |
| Short % of Shares Out | 9.37% |
| Short % of Float | 10.15% |
| Short Ratio (days to cover) | 4.97 |
Income Statement
In the last 12 months, aTyr Pharma had revenue of $235,000 and -$64.02 million in losses. Loss per share was -$0.86.
| Revenue | 235,000 |
| Gross Profit | -54.14M |
| Operating Income | -67.91M |
| Pretax Income | -53.93M |
| Net Income | -64.02M |
| EBITDA | -67.21M |
| EBIT | -67.91M |
| Loss Per Share | -$0.86 |
Full Income StatementBalance Sheet
The company has $72.13 million in cash and $13.28 million in debt, giving a net cash position of $58.84 million or $0.66 per share.
| Cash & Cash Equivalents | 72.13M |
| Total Debt | 13.28M |
| Net Cash | 58.84M |
| Net Cash Per Share | $0.66 |
| Equity (Book Value) | 69.83M |
| Book Value Per Share | 0.83 |
| Working Capital | 66.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$69.12 million and capital expenditures -$65,000, giving a free cash flow of -$69.18 million.
| Operating Cash Flow | -69.12M |
| Capital Expenditures | -65,000 |
| Free Cash Flow | -69.18M |
| FCF Per Share | -$0.78 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -28,899.57% |
| Pretax Margin | -27,243.40% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
aTyr Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.53% |
| Shareholder Yield | -38.53% |
| Earnings Yield | -22.38% |
| FCF Yield | -24.18% |
Analyst Forecast
The average price target for aTyr Pharma is $18.60, which is 466.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.60 |
| Price Target Difference | 466.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 1, 2019. It was a reverse split with a ratio of 0.0714285:1.
| Last Split Date | Jul 1, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.0714285:1 |
Scores
aTyr Pharma has an Altman Z-Score of -5.82. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.82 |
| Piotroski F-Score | n/a |